Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82)
评估将源自端粒酶的 CD4 Th1 诱导癌症疫苗与阿特珠单抗加贝伐珠单抗联合用于不可切除的肝细胞癌的疗效:一项随机非对照 II 期研究 (TERTIO - PRODIGE 82)
期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-023-11065-0
Vienot, Angélique; Jacquin, Marion; Rebucci-Peixoto, Magali; Pureur, Dimitri; Ghiringhelli, François; Assenat, Eric; Hammel, Pascal; Rosmorduc, Olivier; Stouvenot, Morgane; Allaire, Manon; Bouattour, Mohamed; Regnault, Hélène; Fratte, Serge; Raymond, Eric; Soularue, Emilie; Husson-Wetzel, Stéphanie; Di Martino, Vincent; Muller, Allison; Clairet, Anne-Laure; Fagnoni-Legat, Christine; Adotevi, Olivier; Meurisse, Aurélia; Vernerey, Dewi; Borg, Christophe
肿瘤
T细胞
肿瘤免疫
PROD
IGE
细胞生物学
CD4
TERT